Thursday, 5 November 2026European Markets

ADC SIIC Stock Bullish By 26% In The Last 5 Sessions

Loading stream...

paris-based real estate investment company adc siic (aldv.pa) experienced an extraordinary 26.13% surge over five trading sessions from eur0.06 to eur0.07. despite this surge, shares remain 11.88% below their 52-week high of eur0.08.

contextualising adc siic's performance in the broader market

this fluctuation can be put in context with france's cac 40 index, which fell by 1.26% to eur7,312.84 last month. given adc siic is listed on this index, their dramatic stock increase during a general downward trend suggests specific factors have an influence over their shares.

market trends and potential investment opportunities

adc siic's stock performance may reflect current real estate market trends in paris and its suburbs, creating an opportunity for investors to capitalize on adc siic's position within this sector.

adc siic's profitability in spotlight

however, adc siic's profitability details paint an otherwise dim picture: trailing twelve month earnings per share (eps) has been negative at eur-0.01, while they reported a negative return on equity (roe) ratio of -1.87% over this same timeframe, signalling less return for capital provided by shareholders.

insight into adc siic's valuation

closer inspection of adc siic shows that its value exceeds both its 50-day moving average of eur0.07 and 200-day moving average of eur0.07. this indicates a steady upward trend despite fluctuations.

conclusion

in summary, adc siic stands out among other firms due to its rapid stock price appreciation during broader market downturns, coupled with its deep roots in parisian real estate and above-average moving averages despite its profitability issues. these characteristics make adc siic an attractive candidate for investors.

more news about adc siic (aldv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,549 source documents archived
Query this data → isubstrate.com